Loading...
Docoh

Biosynergy (BSYN)

Filed: 15 Dec 20, 5:14pm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended October 31, 2020

 

[_] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to ___________

 

Commission file number 0 -12459

Biosynergy, Inc.

(Exact name of registrant as specified in its charter)

Illinois 36-2880990
(State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

 

1940 East Devon Avenue, Elk Grove Village, Illinois 60007 847-956-0471
(Address of principal executive offices) (Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filing, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

   
Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer (Do not check if a smaller reporting company) ☐ Smaller reporting company ☒
Emerging growth company ☐  

 

If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

APPLICABLE ONLY TO CORPORATE ISSUERS

 

State the number of shares outstanding of each of the issuer’s classes of common stock, as of October 31, 2020: 14,935,511

 

 

 
 

 

BIOSYNERGY, INC.

 

PART 1 - FINANCIAL INFORMATION

 

Item 1. Financial Statements and Supplementary Data

 

 

BALANCE SHEETS

 

  October 31, 2020
Unaudited
 April 30, 2020
Audited
Assets
Current Assets        
Cash
 $1,260,141  $1,245,282 
Accounts receivable. Trade (net of allowance for doubtful accounts of $500) at October 31, 2020 and April 30, 2020  262,134   262,939 
Inventories  133,255   144,423 
Prepaid expenses  29,600   43,480 
Total Current Assets  1,685,130   1,696,124 
Property, Plant and Equipment        
Equipment  200,590   200,590 
Leasehold improvements  25,809   25,809 
   226,399   226,399 
Less accumulated depreciation and amortization  (221,104)  (218,872)
Total Equipment and Leasehold Improvements Net  5,295   7,527 
Operating Lease Right of Use        
Operating Lease Right of Use Asset  144,855   193,140 
Total Operating Lease Right of Use Asset  144,855   193,140 
Other Assets        
Patents less accumulated amortization  98,237   105,058 
Deposits  5,937   5,937 
Total other assets  104,174   110,995 
  $1,939,454  $2,007,786 

The accompanying notes are an integral part of the financial statements.

 

 

BIOSYNERGY, INC.

 

PART 1 - FINANCIAL INFORMATION

 

 

BALANCE SHEETS

 

  October 31, 2020
Unaudited
 April 30, 2020
Audited
Liabilities and Shareholders’ Equity
Current Liabilities        
Accounts payable $4,711  $23,114 
Accrued compensation and payroll taxes  11,806   19,996 
Accrued vacation  18,912   28,089 
Other accrued liabilities  529   434 
Operating lease liability  96,570   95,160 
Total Current Liabilities  132,528   166,793 
             
Long term Liabilities        
Deferred income taxes  19,812   19,812 
Operating lease liability – long term  48,990   97,980 
Total long term liabilities  68,802   117,792 
Stockholders’ Equity        
Common stock, no par value: 20,000,000 authorized
Shares issued: 14,935,511 shares at October 31, 2020
and April 30, 2020
  660,988   660,988 
Receivable from affiliate  (24,862)  (24,862)
Retained earnings  1,101,998   1,087,075 
Total Stockholders’ Equity  1,738,124   1,723,201 
   1,939,454   2,007,786 

The accompanying notes are an integral part of the financial statements

 

 

 

 

 

BIOSYNERGY, INC.

 

Statements of Operations

(Unaudited)

 

 

  Three Months Ended Six Months Ended
  October 31 October 31
  2020 2019 2020  2019
Net sales $313,508  $312,303  $604,959   629,085 
Cost of sales  109,935   108,553   221,818   215,727 
Gross profit  203,573   203,750   383,141   413,358 
Operating expenses                
Marketing  39,069   43,766   84,155   91,568 
General and administrative  88,953   97,678   202,492   208,194 
Research and development  36,787   39,175   76,840   79,097 
Total Operating Expenses  164,809   180,619   363,487   378,859 
                 
Income from operations  38,764   23,131   19,654   34,499 
Other income                
Interest income  115   150   257   300 
Other income  480   480   960   960 
Total Other Income  595   630   1,217   1,260 
                 
Net income before income taxes  39,359   23,761   20,871   35,759 
                 
Provision for income taxes  11,217   6,771   5,948  $10,191 
Net income $28,142  $16,990  $14,923  $25,568 
Net income per common share - basic and diluted $.0019 $.0011  $.0010  $.0017 
Weighted-Average Shares of Common Stock Outstanding - Basic and Diluted  14,935,511   14,935,511   14,935,511   14,935,511 

 

The accompanying notes are an integral part of the financial statements.

 

 

 

 

 

 

BIOSYNERGY, INC.

 

STATEMENT OF SHAREHOLDERS' EQUITY

 

SIX MONTHS ENDED OCTOBER 31, 2020

 

 

Common Stock

  

Shares 

 

Amounts

 

Receivable from Affiliate

 

Retained Earnings

 

Total

Balance, May 1, 2020  14,935,511  $660,988  $(24,862) $1,087,075  $1,723,201 
Net Income  —     —     —    $14,923  $14,923 
Balance, October 31, 2020  14,935,511  $660,988  $(24,862) $1,101,998  $1,738,124 

The accompanying notes are an integral part of the financial statements.

 

 

 

 

 

BIOSYNERGY, INC.

 

STATEMENTS OF CASH FLOWS

(Unaudited)

 

  Six Months Ended October 31
     2020   2019
Cash flows from operating activities        
Net income $14,923  $25,568 
Adjustments to reconcile net income to cash provided by
operating activities
        
Depreciation and amortization  9,053   9,659 
Noncash lease expense  48,285   44,550 
Changes in assets and liabilities        
Accounts receivable  805   4,173 
Inventories  11,168   5,719 
Prepaid expenses  13,880   17,822 
Accounts payable and accrued expenses  (35,675)  (18,346)
Building lease liability for right of use asset  (47,580)  (45,100)
Total adjustments  (64)  18,477 
Net cash provided by operating activities  14,859   44,045 
Increase in cash and cash equivalents  14,859   44,045 
Cash and cash equivalents beginning period  1,245,282   1,180,125 
Cash and cash equivalents ending period $1,260,141  $1,224,170 
Supplemental Cash Flow information        
Interest paid $—    $—   
Income taxes paid $—    $—   

 

 

The accompanying notes are an integral part of the financial statements.

 

 

 

BIOSYNERGY, INC.

Notes to Financial Statements

Six Months Ended October 31, 2020 and 2019

 

Note 1 - Company Organization and Description

 

In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments, consisting of normal recurring adjustments which are necessary for a fair presentation of the financial position and results of operations for the periods presented. The unaudited condensed financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all the information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America. These condensed financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s April 30, 2020 Annual Report on Form 10-K. The results of operations for the six months ended October 31, 2020 are not necessarily indicative of the operating results for the full year.

 

Biosynergy, Inc. (the Company) was incorporated under the laws of the State of Illinois on February 9, 1976. It is primarily engaged in the development and marketing of medical, consumer and industrial thermometric and thermographic products that utilize cholesteric liquid crystals. The Company’s primary product, the HemoTemp II Blood Monitoring Device, accounted for approximately 88.2% of the sales during the six months ending October 31, 2020 and 91.89% during the six months ending October 31, 2019. The products are sold to hospitals, clinical end-users, laboratories and product dealers located throughout the United States.

 

Note 2 - Summary of Significant Accounting Policies

 

Cash

 

The Company maintains all of its cash in various bank deposit accounts, which at times may exceed federally insured limits. No losses have been experienced on such accounts.

 

Receivables

 

Receivables are carried at original invoice less estimates made for doubtful receivables. Management determines the allowances for doubtful accounts by reviewing and identifying troubled accounts on a periodic basis and by using historical experience applied to an aging of accounts. A receivable is considered to be past due if any portion of the receivable balance is outstanding beyond the stipulated due date. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received.

 

Inventories

 

Inventories are valued at the lower of cost or market using the FIFO (first-in, first-out) method.

 

Depreciation

 

Equipment and leasehold improvements are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred; renewals and betterments which significantly extend the useful lives of existing equipment are capitalized. Significant leasehold improvements are capitalized and amortized over the term of the lease; equipment is depreciated over three to ten years.

 

Depreciation expense was $2,232 and $2,837 for the six month periods ending October 31, 2020 and 2019, respectively.

 

 

 

 

BIOSYNERGY, INC.

Notes to Financial Statements

Six Months Ended October 31, 2020 and 2019

 

Note 2 - Summary of Significant Accounting Policies (Cont’d)

 

Prepaid Expenses

 

Certain expenses, primarily insurance and income taxes, have been prepaid and will be used within one year.

 

Revenue Recognition

 

The Company accounts for revenue in accordance with ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)". The core principle of ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance provides a five-step process to achieve that core principle and to determine when and how revenue is recognized.

 

The components as it relates to the Company are as follows:

 

The Company’s revenue is primarily generated from the sales of products directly to customers or through distribution channels, based on purchase orders and not supply contracts providing for additional goods or services once the products are transferred to the customer. The Company believes its performance obligations are satisfied upon shipment of goods to customers. The customers are billed at shipment, and revenue is recognized by the Company at that time.
ASU No. 2014-09 requires that the Company recognize its sales return allowance on a gross basis rather than as a net liability. As such, the Company now recognizes a return asset for the right to recover the goods returned by the customer, measured at the former carrying amount of the products, less any expected recovery costs (recorded as an increase to prepaid expenses and other current assets), and a return liability for the amount of expected returns (recorded as an increase to other current liabilities). The Company’s analysis of sales returns over the past several years noted that sales returns are nominal and therefore no sales return allowance is deemed necessary.

 

Shipping and Handling

 

Shipping and handling fees billed to customer, if any, are netted against the related costs which are included in cost of sales. The net cost is not material.

 

Income Taxes

 

Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes related primarily to differences in the methods of accounting for patents, inventories, certain accrued expenses and bad debt expenses for financial and income tax reporting purposes. The deferred income taxes represent the future tax consequences of those differences, which will be taxable in the future.

 

 

 

 

 

BIOSYNERGY, INC.

Notes to Financial Statements

Six Months Ended October 31, 2020 and 2019

 

 

Note 2 - Summary of Significant Accounting Policies (Cont’d)

 

The Company files tax returns in the U.S. federal jurisdiction and with the state of Illinois. Various tax years remain open to examinations, generally for three years after filing, although there are currently no ongoing tax examinations. Management’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense.

 

The provision for income taxes consists of the following components for the six month periods ended October 31:

 

 2020 2019
Current        
Federal $3,965  $6,794 
State  1,983   3,397 
Provision for Income Taxes $5,948  $10,191 

 

The differences between the U.S. federal statutory tax rate and the Company’s effective tax rate are as follows:

 

  Period ended October 31,
  2020 2019
U.S. federal statutory tax rate  21%  21%
State income tax expense, net of      Federal tax benefit  7.5%  7.5%
Effective Tax Rate  28.5%  28.5%

 

Research and Development and Patents

 

Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and once obtained, are amortized over the life of the respective patent on the straight-line method.

 

Patent amortization expense for each of the six months ended October 31, 2020 and 2019 were $6,822.

 

Patents relate to products that have been developed and are being marketed by the Company. Patents pending relate to products under development.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

 

 

 

BIOSYNERGY, INC.

Notes to Financial Statements

Six Months Ended October 31, 2020 and 2019

 

Note 2 - Summary of Significant Accounting Policies (Cont’d)

 

Income Per Common Share

 

Income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Basic and diluted net income per common share is the same for the six months ended October 31, 2020 and 2019 as there are no common stock equivalents.

 

Comprehensive Income

 

Components of comprehensive income include amounts that are included in the comprehensive income but are excluded from net income. During the six month periods ending October 31, 2020 and 2019, there were no differences between the Company’s net income and comprehensive income.

 

Fair Value of Financial Instruments

 

The Company evaluates its financial instruments based on current market interest rates relative to stated interest rates, length to maturity and the existence of readily determinable market prices. Based on the Company’s analysis, the fair value of financial instruments recorded on the balances sheets as of October 31, 2020 and April 30, 2020, approximates their carrying value.

 

Segments

 

Accounting standards have established annual reporting standards for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. The Company’s operations were a single reportable segment and an international segment. The international segment operations are immaterial. See Note 7.

 

Recent Accounting Pronouncements

 

The FASB issues ASUs to amend the authoritative literature in Accounting Standards Certification (ASC). There have been a number of ASUs to date that amend the original text of ASCs. Those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company.

 

 

10 
 

 

BIOSYNERGY, INC.

Notes to Financial Statements

Six Months Ended October 31, 2020 and 2019

 

Note 3 – Inventories

 

Components of inventories are as follows:

  

  October 31, 2020 April 30, 2020
Raw materials $99,137  $106,284 
Work-in-process  24,238   26,919 
Finished goods  9,880   11,220 
  $133,255  $144,423 

 

Note 4 – Common Stock

 

The Company’s common stock is traded in the over-the-counter market. However, there is no established public trading market due to limited and sporadic trades. The Company’s common stock is not listed on a recognized market or stock exchange.

 

Note 5 - Related Party Transactions

 

The Company and its affiliates are related through common stock ownership as follows as of October 31, 2020:

 

Stock of Affiliates

____________________________________

 

  Biosynergy, Inc.     F.K. Suzuki International, Inc. 

Medlab, Inc.

F.K. Suzuki International, Inc  30.0%  —  %  100.0%
Fred K. Suzuki, Officer  4.1   30.0   —   
Jeanne S. Addis, Trustee  —     28.1   —   
Mary K. Friske, Officer  0.3   0.7   —   
Laurence C. Mead, Officer  0.4   10.0   —   
Beverly R. Suzuki  2.7   —     —   
Lauane C. Addis, Officer  —     —     —   
Malcolm MacCoun, Director
  —     —     —   
11 
 

 

BIOSYNERGY, INC.

Notes to Financial Statements

Six Months Ended October 31, 2020 and 2019

 

Note 5 - Related Party Transactions (Cont’d)

 

As of October 31, 2020 and April 30, 2020, $24,862 was due from F. K. Suzuki International, Inc. These balances result from an allocation of common expenses charged to FKSI prior to April 30, 2006 offset by advances received from time to time, including an advance of $5,163 in Fiscal 2020 for corporate compliance costs. No interest income is received or accrued by the Company. The financial condition of FKSI is such that it will unlikely be able to repay the Company during the next year without liquidating a portion of its assets, including a portion of its ownership in the Company. As a result, the receivable balance has been reclassified as a contra equity account.

 

A board member provided a variety of legal services to the Company in his capacity as a partner in a law firm. Fees for such legal services were approximately $6,002 and $7,585 for the six months ended October 31, 2020 and 2019 respectively.

 

Note 6 – Lease Commitments

 

On February 25, 2016, the FASB issued Topic 842, Leases. Under its core principle, a lessee will recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. Lessor accounting remains largely consistent with existing U.S. GAAP. At inception, a lessee must classify all leases as either finance or operating. In February 2020, the Company entered into a two-year lease agreement for its current facilities, which started May 1, 2020 and expires on April 30, 2022. Under the new lease standard, the Company’s lease was accounted for as an operating lease. As a result, the Company measured the lease liability using the two year term and rates per the lease agreement and recognized a lease liability, with a corresponding right-of-use asset. A discount was not calculated due to the lease agreement only having a two year term.

 

The operating lease expense for the six months ending October 31, 2020 and 2019 was $48,285 and $44,550, respectively.

 

Maturities of lease liabilities as of October 31, 2020 are presented in the following table:

 

 Year Ending April 30:
2021 $48,285 
2022 $96,570 

 

Note 7 – Customer Concentrations

 

Shipments to one customer amounted to 32.04% of sales during the first six months of Fiscal 2021 compared to 26.95% during the comparative Fiscal 2020 period. As of October 31, 2020, there were outstanding accounts receivable from this customer of $82,190 compared to $73,825 at October 31, 2019. Shipments to another customer amounted to 36.57% of sales during the first six months of Fiscal 2021 and 37.10% of sales during the first six months of Fiscal 2020. As of October 31, 2020, there were outstanding accounts receivable from this customer of $136,555 compared to $134,288 at October 31, 2019.

 

 

 

12 
 

 

 

 

BIOSYNERGY, INC.

Notes to Financial Statements

Six Months Ended October 31, 2020 and 2019

 

Note 7 – Customer Concentrations (Cont’d)

 

The Company had export sales of $9,930 during the 2nd Quarter of Fiscal 2021, and export sales of $15,295 during the 2nd Quarter of Fiscal 2020. For the six months ending October 31, 2020 export sales were $21,570 and $22,605 for the same period ending October 31, 2019. The Company also believes that some of its medical devices were sold to distributors within the United States who resold the devices in foreign markets. However, the Company does not have any information regarding such sales and such sales are not considered to be material.

 

Note 8 – COVID-19 Pandemic

 

The Company will face challenges in 2020 and 2021 as a result of the COVID-19 pandemic. Such challenges will include (among other things) decreases or significant decreases in demand for certain products that has resulted in a decrease in sales for the six months ending October 31, 2020, and increases in demand for others, collectability of customer accounts receivable from customers negatively impacted by shelter in place requirements, managing the health and productivity of our employees working in our facility or working remotely, managing our information technology (IT) infrastructure and security for our employees working remotely, and procuring adequate raw materials and packaging, as well as managing our supply chain. We have also worked closely with our domestic suppliers to source and maintain a consistent supply of raw material, ingredients and packaging to provide a steady supply of our products to our customers. We are fortunate that to date our manufacturing facility has not been significantly impacted by this pandemic.

 

 

13 
 

 

 

 

BIOSYNERGY, INC.

Six Months Ended October 31, 2020 and 2019

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Net Sales/Revenues

 

For the three month period ending October 31, 2020 (“2nd Quarter”), the net sales increased .39%, or $1,205, and decreased 3.84%, or $24,126, during the six month period ending October 31, 2020, as compared to net sales for the comparative periods ending in 2019. This decrease in sales is primarily the result of a decrease in the sales of HemoTemp® II, offset by an increase of LabTemp® 20 in the 2nd Quarter. As of October 31, 2020, the Company had no back orders.

 

In addition to the above, the Company had $595 and $1,217 of other miscellaneous revenues primarily from interest income and leasing a portion of its storage space to a third party during the three and the six month periods ending October 31, 2020, respectively.

 

Costs and Expenses General

 

The operating expenses of the Company during the 2nd Quarter decreased overall by 8.75%, or $15,810, and decreased by 4.06%, or $15,372, for the six month period ending October 31, 2020, as compared to the same periods ending in 2019. The decrease during the 2nd Quarter and for the six month period ending October 31, 2020 was due to a decrease in legal, accounting and advertising fees, salaries and employee expenses.

 

Cost of Sales

 

The overall cost of sales during the 2nd Quarter increased by $1,382 and increased by $6,091 during the six month period ending October 31, 2020 as compared to the same periods ending in 2019. For the six months ended October 31, 2020, the increase was due to higher raw material costs. As a percentage of sales, the cost of sales were 35.07% during the 2nd Quarter and 34.76% for the comparative quarter ending in 2019; and 36.67% during the six month period ending October 31, 2020 compared to 34.29% in 2019. It is not anticipated that the cost of sales as a percentage of sales will materially change in the near future.

 

Research and Development Expenses

 

Research and Development costs decreased $2,388, or 6.1%, during the 2nd Quarter as compared to the same quarter in 2019. These costs decreased by $2,257, or 2.85%, during the six month period ending October 31, 2020 as compared to the same period in 2019. This decrease was primarily due to lower employee costs and company car expenses.

 

14 
 

BIOSYNERGY, INC.

Six Months Ended October 31, 2020 and 2019

 

Marketing Expenses

 

Marketing expenses for the 2nd Quarter decreased by $4,697, or 10.73%, as compared to the quarter ending October 31, 2019 and decreased by $7,413 or 8.1%, during the six month period ending October 31, 2020 compared to the six-month period ending October 31, 2019. The change in marketing expenses for the six-month period ending October 31, 2020 compared to the six-month period ending October 31, 2019 was primarily due to lower salaries, employee expenses, advertising fees and travel and entertainment expenses.

 

General and Administrative Expenses

 

General and administrative costs decreased by $8,725, or 8.93%, in the 2nd Quarter, and decreased by $5,702, or 2.74%, during the six month period ending October 31, 2020, as compared to the same periods in 2019. This overall decrease for the six months ending October 31, 2020 was due primarily to lower legal and accounting fees and a decrease in employee costs. Except for unforeseen items and ordinary cost increases, it is unlikely general and administrative expenses will materially change during the remainder of Fiscal 2021.

 

Net Income

 

The Company realized a net income of $28,142 during the 2nd Quarter as compared to a net income of $16,990 for the comparative quarter in the prior year. The Company also realized a net income of $14,923 for the six month period ending October 31, 2020 as compared to a net income of $25,568 during the same period in 2019. The decrease in net income is a result of decreased net sales for the six month period ending October 31, 2020.

 

Assets/Liabilities

General

 

Since April 30, 2020, the Company’s assets have decreased by $68,332 and liabilities have decreased by $83,255. The overall decrease in assets and liabilities is primarily due to the changes in the accounting treatment for leases, which include amortization of the right of use asset and payments against the lease liability.

 

Related Party Transactions

 

As of October 31, 2020 and April 30, 2020, $24,862 was due from F. K. Suzuki International, Inc. These balances result from an allocation of common expenses charged to FKSI prior to April 30, 2006 offset by advances received from time to time, including an advance of $5,163 in Fiscal 2020 for corporate compliance costs. No interest income is received or accrued by the Company. The financial condition of FKSI is such that it will unlikely be able to repay the Company during the next year without liquidating a portion of its assets, including a portion of its ownership in the Company. As a result, the receivable balance has been reclassified as a contra equity account.

 

A board member provides a variety of legal services to the Company in his capacity as a partner in a law firm. Fees for such legal services were approximately $6,002 and $7,585 for the six months ended October 31, 2020 and 2019, respectively.

 

15 
 

BIOSYNERGY, INC.

Six Months Ended October 31, 2020 and 2019

 

Current Assets/Liabilities Ratio

 

The ratio of current assets to current liabilities, 12.7 to 1, has increased compared to 10.2 to 1 at April 30, 2020, primarily due to higher cash balances and lower accounts payable and accrued liabilities. The Company anticipates the ratio of current assets to current liabilities will remain substantially at its current level as a result of the change in accounting methods, subject to other normal fluctuations. In order to maintain or improve the Company’s asset/liabilities ratio, the Company’s operations must remain profitable.

 

Liquidity and Capital Resources

 

During the six month period ending October 31, 2020, the Company experienced an increase in working capital of $23,271. This was primarily due to higher cash balances and lower accrued liabilities and lower operating lease liability.

 

The Company has attempted to conserve working capital whenever possible. To this end, the Company attempts to keep inventory at minimum levels. The Company believes that it will be able to maintain adequate inventory to supply its customers on a timely basis by careful planning and forecasting demand for its products. However, the Company is nevertheless required to carry a minimum amount of inventory to meet the delivery requirements of customers and thus, inventory represents a substantial portion of the Company’s investment in current assets.

 

The Company presently grants payment terms to customers and dealers. Although the Company experiences varying collection periods of its account receivable, the Company believes that uncollectable accounts receivable will not have a significant effect on future liquidity.

 

The cash provided by operating activities was $14,859 during the six month period ending October 31, 2020. Except for its operating working capital, limited equipment purchases and patent prosecution costs, management is not aware of any other material capital requirements or material contingencies for which it must provide. There were no cash flows from financing or investing activities during the six month period ending October 31, 2020.

 

As of October 31, 2020, the Company had $1,685,130 of current assets available. Of this amount, $29,600 was prepaid expenses, $133,255 was inventory, $262,134 was net trade receivables and $1,260,141 was cash. The Company’s available cash and cash flow are considered adequate to fund the short-term capital needs of the Company. The Company does not have a working line of credit, and does not anticipate obtaining a working line of credit in the near future. Thus there is a risk additional financing may be necessary to fund long-term capital needs of the Company, although there is no such currently known long-term capital needs other than operations.

 

16 
 


BIOSYNERGY, INC.

Six Months Ended October 31, 2020 and 2019

 

Effects of Inflation. With the exception of inventory, labor costs and product sales prices increasing with inflation, inflation has not had a material effect on the Company’s revenues and income from continuing operations in the past three years. Inflation is not expected to have a material effect in the foreseeable future.

 

Critical Accounting Policies and Estimates. On December 12, 2001, the SEC issued FR-60 “Cautionary Advice Regarding Disclosure About Critical Accounting Policies.” FR-60 is an intermediate step to alert companies to the need for greater investor awareness of the sensitivity of financial statements to the methods, assumptions, and estimates underlying their preparation, including the judgments and uncertainties affecting the application of those policies and the likelihood that materially different amounts would be reported under different conditions or using different assumptions.

 

The Company’s significant accounting policies are disclosed in Note 2 to the Financial Statements for the 2nd Quarter. See “Financial Statements.” Except as noted below, the impact on the Company’s financial position or results of operation would not have been materially different had the Company reported under different conditions or using different assumptions. The policies which may have materially affected the financial position and results of operations of the Company if such information had been reported under different circumstances or assumptions are:

 

Lease Commitments - On February 25, 2016, the FASB issued Topic 842, Leases.  Under its core principle, a lessee will recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months.  Lessor accounting remains largely consistent with existing U.S. GAAP.  At inception, a lessee must classify all leases as either finance or operating. The Company classifies the lease for its facility in Elk Grove Village as an operating lease.

 

Revenue Recognition - In May 2014, the Financial Accounting Standard Board (FASB) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition, and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance provides a five-step process to achieve that core principle and to determine when and how revenue is recognized.

 

Use of Estimates. Preparation of financial statements and conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the Financial Statements and the reported amounts of revenues and expenses during the reporting period. The financial condition of the Company and results of operations may differ from the estimates and assumptions made by management in preparation of the Financial Statements accompanying this report.

 

Allowance for Bad Debts. The Company periodically performs credit evaluations of its customers and generally does not require collateral to support amounts due from the sale of its products. The Company maintains an allowance for doubtful accounts based on its best estimate of accounts receivable.

 

17 
 

 

BIOSYNERGY, INC.

Six Months Ended October 31, 2020 and 2019

 

Forward-Looking Statements

 

This report may contain statements which, to the extent they are not recitations of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Such forward-looking statements involve risks and uncertainties. Actual results may differ materially from such forward-looking statements for reasons including, but not limited to, changes to and developments in the legislative and regulatory environments effecting the Company’s business, the impact of competitive products and services, changes in the medical and laboratory industries caused by various factors, risks inherit in marketing new products, as well as other factors as set forth in this report. Thus, such forward-looking statements should not be relied upon to indicate the actual results which might be obtained by the Company. No representation or warranty of any kind is given with respect to the accuracy of such forward-looking information. The forward-looking information has been prepared by the management of the Company and has not been reviewed or compiled by independent public accountants.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates and commodity prices. The Company’s primary exposure to market risk is interest rate risk associated with its short term money market investments. The Company does not have any financial instruments held for trading or other speculative purposes and does not invest in derivative financial instruments, interest rate swaps or other investments that alter interest rate exposure. The Company does not have any credit facilities with variable interest rates. The Company’s operations are not exposed to financial risk that will have a material impact on its financial position and results of operation.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a15(e) and 15d-15(e) of the Exchange Act) which are controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms.

 

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Accounting Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company’s Chief Executive Officer and Chief Accounting Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company’s Chief Executive Officer and its Chief Accounting Officer have concluded that the Company’s disclosure controls and procedures were effective.

 

18 
 

 

BIOSYNERGY, INC.

Six Months Ended October 31, 2020 and 2019

 

There have been no changes in the Company’s internal control over financial reporting during the Company’s Fiscal Quarter ending October 31, 2020 that have materially affected or are likely to materially affect the Company’s internal control over financial reporting.

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

As of the end of the Company’s Fiscal Quarter ending October 31, 2020, there are no material pending legal proceedings to which the Company or any of its subsidiaries is a party to of which any of their property is the subject.

 

Item 1A. Risk Factors.

 

In addition to the other information set forth in this report on Form 10-Q, you should also consider the factors, risks and uncertainties which could materially affect the Company’s business, financial condition or future results as discussed in Part I, Item 1A – “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended April 30, 2020. There were no significant changes to the risk factors identified on the Form 10-K for the fiscal year ended April 30, 2020 or during the second quarter of Fiscal 2021.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

During the past three years, the Company has not sold securities which were not registered under the Securities Act.

 

Item 3. Defaults Upon Senior Securities.

 

(a)        As of the end of the Company’s Fiscal Quarter ending October 31, 2020, there have been no material defaults in the payment of principal, interest, a sinking or purchase fund installment, or any other material default not cured within 30 days, with respect to any indebtedness of the registrant or any of its significant subsidiaries exceeding 5 percent of the total assets of the Company and its consolidated subsidiaries.

 

(b)                As of the end of the Company’s Fiscal Quarter ending October 31, 2020, there have been no material arrearages in the payment of dividends and there has been no other material delinquency not cured within 30 days, with respect to any class of preferred stock of the Company which is registered or which ranks prior to any class of registered securities, or with respect to any class of preferred stock of any significant subsidiary of the Company.

 

Item 4. Mine Safety Disclosures.

 

The disclosures required by this Item are not applicable to the Company.

 

 

19 
 

 

 

 

 

BIOSYNERGY, INC.

Six Months Ended October 31, 2020 and 2019

 

 

Item 5. Other Information.

 

(a)The Company is not required to disclose any information in this Form 10-Q otherwise required to be disclosed in a report on Form 8-K during the period covered by this Form 10-Q.

 

(b)During the Fiscal Quarter ending October 31, 2020, there have been no material changes to the procedures by which the security holders may recommend nominees to the Company’s board of directors, where such changes were implemented after the Company last provided disclosure in response to the requirements of Regulation S-K.

 

Item 6. Exhibits.

 

The following exhibits are filed as a part of this report:

 

(2)Plan of Acquisition, reorganization, arrangement, liquidation or succession - none

 

(3)Articles of Incorporation and By-laws(i)

 

(4)Instruments defining rights of security holders, including indentures - none.

 

(10)Material Contracts – none.

 

(11)Statement regarding computation of per share earnings- none.

 

(15)Letter regarding unaudited interim financial information - none.

 

(18)Letter regarding change in accounting principles - none.

 

(19)Reports furnished to security holders - none.

 

(22)Published report regarding matters submitted to vote of security holders - none.

 

(23)Consents of experts and counsel - none.

 

20 
 

 

BIOSYNERGY, INC.

Six Months Ended October 31, 2020 and 2019

(24)Power of Attorney - none.

(31.1)Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. Filed herewith.

 

(31.2)Certification of the Chief Accounting Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. Filed herewith.

 

(32.1)Certification of the Chief Executive Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Sect. 1350. Filed herewith.

 

(32.2)Certification of the Chief Accounting Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Sect. 1350. Filed herewith.
___________________

(i) Incorporated by reference to a Registration Statement filed on Form S-18 with the Securities and Exchange Commission, 1933 Act Registration Number 2-38015C, under the Securities Act of 1933, as amended, and Incorporated by reference, with regard to Amended and Restated By-Laws, to the Company’s Current Statement on Form 8-K dated as of July 2, 2009 filed with the Securities and Exchange Commission.

21 
 

 

BIOSYNERGY, INC.

Six Months Ended October 31, 2020 and 2019

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 Biosynergy, Inc.
  
  By:/s/ Fred K. Suzuki
  Fred K. Suzuki
Chief Executive Officer, Chairman of the Board, and President

  
  By:/s/ Laurence C. Mead
  Laurence C. Mead
Chief Operating Officer, Chief Financial Officer, Chief Accounting Officer, and Treasurer

Date:  December 15, 2020


22